Tina van Tonder

National usage of cryoprecipitate in massive haemorrhage

Maxine Revoltar, Kirsten Caithness, Tina van Tonder, Lesley Survela et autres

au (code pays fourni par la source)

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Cole‐Sinclair et autres

PD23 Economic Evaluation Of Prophylactic Immunoglobulin Versus Prophylactic Antibiotics In Hematological Malignancies: Results From The RATIONAL Feasibility Trial

Sara Carrillo de Albornoz, Alisa M. Higgins, Dennis Petrie, Adam Irving et autres

Introduction Patients with hematological malignancies are at high risk of infections due to both the disease and the associated treatments. The use of immunoglobulin (Ig) to prevent infections is increasing in this population, but its cost effectiveness is unknown. This trial-based economic …

Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy

Zoe McQuilten, Robert Weinkove, Lê Thị Phương Thảo, Philip Crispin et autres

ABSTRACT: Immunoglobulin replacement and prophylactic antibiotics are commonly used to prevent infections in patients with secondary hypogammaglobulinemia due to hematological malignancies but have never been directly compared. In this randomized controlled feasibility trial conducted in 7 hospitals in Australia and New Zealand, …

au, nz (code pays fourni par la source)

Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies

Sara Carrillo de Albornoz, Alisa M. Higgins, Dennis Petrie, Adam Irving et autres

ABSTRACT: Patients with hematological malignancies are at high risk of developing hypogammaglobulinemia (HGG) and infections. Immunoglobulin (Ig) is one recommended option to prevent these infections, but it is expensive, and its cost-effectiveness compared with other prevention strategies remains unknown. We conducted a …

au, nz (code pays fourni par la source)

P-476 More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial

Elizabeth Moore, Simon J. Harrison, Phoebe Joy Ho, Adam Irving et autres

PB2698: MORE EFFICIENT DELIVERY OF HIGH-COST STANDARD-OF-CARE THERAPIES IN RELAPSED MULTIPLE MYELOMA USING REAL-TIME FEEDBACK OF PATIENT-REPORTED OUTCOME MEASURES: THE MY-PROMPT-2 TRIAL

Elizabeth Moore, Simon J. Harrison, P. Joy Ho, Adam Irving et autres

Topic: 35. Quality of life and palliative care Background: Despite advances in treatment of multiple myeloma (MM), real-world data show that survival benefits achieved with newer therapies in clinical trials are not seen in clinical practice. Moreover, newer MM therapies with multiple …

au (code pays fourni par la source)